Bed Rest Study SBI 2023

Sponsor
Science and Research Centre Koper (Other)
Overall Status
Completed
CT.gov ID
NCT06141291
Collaborator
Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI) (Other), Izola General Hospital (Other), University of Padova (Other), University of Udine (Other), University of Pavia (Other), University of Trieste (Other)
29
1
3
2
14.2

Study Details

Study Description

Brief Summary

The study will consist of three groups of subjects. Ten young male subjects (18-30 years) will lie supine for 21 days, 10 older male subjects (65+ years) will lie supine for 10 days, and a third group of 10 older male subjects (65+ years) will also lie supine for 10 days but will receive interventions (see below) to counteract the physical changes caused by supine lying. All three groups will be bedridden in the premises of Izola General Hospital. Subjects will be housed in 5-bed rooms at the hospital and will receive 24-hour medical care, proper hygiene, nutrition, passive exercise, Internet, a relaxing environment, and visits. After their stay, subjects return home but receive 21 days of care at local fitness centers. Rehabilitation consists of interval training, in which subjects perform high-intensity exercise for 4 times 5 minutes. A number of important health parameters are measured before, during, and after bed rest. Some of these measurements will be invasive (blood and muscle sampling), for which appropriate medical personnel, sterile instruments, and environment will be available. Measurements will include normal voluntary efforts (indoor cycling, various jumps, short stretches) and electrically evoked muscle contractions (electrical stimulation with single impulses). All tests are normal tests and come from normal lifestyles and routine medical examinations.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: High protein diet
  • Diagnostic Test: OGTT
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
29 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Neuromuscular Decline After Physical Inactivity: a Comparison of Younger and Older Adults
Actual Study Start Date :
Aug 21, 2023
Actual Primary Completion Date :
Oct 22, 2023
Actual Study Completion Date :
Oct 22, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Old 1

1. Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.

Diagnostic Test: OGTT
Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.

Experimental: Old 2

Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects. Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.

Dietary Supplement: High protein diet
Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.

Diagnostic Test: OGTT
Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.

Other: Young

1. Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.

Diagnostic Test: OGTT
Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.

Outcome Measures

Primary Outcome Measures

  1. Insulin sensitivity [10 days]

    Assessment in changes in insulin sensitivity will be made with the use of Oral Glucose Tolerance test (OGTT).

Secondary Outcome Measures

  1. Muscle mass [10 day]

    Muscle mass will be measured with bioimpedance and with DXA.

  2. Muscle force [10 days]

    Quadriceps femoris maximal voluntary contractions (MVC) in isometric conditions at knee angle set at 30 deg flexion and hip fixed at 90 deg flexion using a custom-made knee dynamometer fitted with a load cell (RS 206-0290).

  3. Neuromuscular junction stability [10 days]

    We will evaluate the presence of NMJ stability by analysing: AChR subunits expression

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • age: for young arm (18-35), for old arm (65-75)

  • BMI: 22 in 32 kg/m2

  • appendicular muscle mass > 7,23 kg/m2

Exclusion Criteria:
  • serious acute or chronic diseases: skeletal, cancer, cardiovascular, metabolic, neuromuscular and psychiatric;

  • cardiovascular disease detected on ECG examination;

  • allergies to the active substances used in the study;

  • problems with digestion of the active substances;

  • frequent diarrhea and vomiting;

  • arterial hypertension (>140/90 mmHg);

  • psychological problems;

  • susceptibility to deep vein thrombosis (D-dimer < 500 μg/L)

  • poor orthostatic tolerance (frequent dizziness when changing position, especially when rising from a supine position);

  • venous abnormalities that would cause difficulty in drawing blood;

  • a large blood volume (more than 300 ml) in the last 3 months prior to the start of the project;

  • problems with excessive consumption of alcoholic beverages;

  • active smoking;

  • Previous participation in any biomedical research in the last 3 months prior to the start of this study;

  • a communicable disease before the start of the project;

  • any ferromagnetic implant.

Contacts and Locations

Locations

Site City State Country Postal Code
1 SRC Koper Koper Slovenia 6000

Sponsors and Collaborators

  • Science and Research Centre Koper
  • Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI)
  • Izola General Hospital
  • University of Padova
  • University of Udine
  • University of Pavia
  • University of Trieste

Investigators

  • Principal Investigator: Rado Pišot, PhD, Science and Research Centre Koper

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rado Pisot, Director, Scientific councillor, Science and Research Centre Koper
ClinicalTrials.gov Identifier:
NCT06141291
Other Study ID Numbers:
  • BEDREST
First Posted:
Nov 21, 2023
Last Update Posted:
Nov 21, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 21, 2023